An open-label, single-treatment, single-period, single dose, clinical phase 1 study to assess the safety and tolerability of Diphtheria, Tetanus, Pertussis (whole cell), Hepatitis B (rDNA) and Haemophilus type B conjugate vaccine (adsorbed) I.P. of M/S Cadila healthcare Ltd., India in healthy, adult, male, human subjects.

Trial Profile

An open-label, single-treatment, single-period, single dose, clinical phase 1 study to assess the safety and tolerability of Diphtheria, Tetanus, Pertussis (whole cell), Hepatitis B (rDNA) and Haemophilus type B conjugate vaccine (adsorbed) I.P. of M/S Cadila healthcare Ltd., India in healthy, adult, male, human subjects.

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs Diphtheria tetanus and pertussis vaccine (Primary) ; Hepatitis B vaccine (Primary) ; Hib vaccine (Primary)
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Tetanus
  • Focus Adverse reactions
  • Sponsors Cadila Healthcare
  • Most Recent Events

    • 31 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top